**WEB REQUIREMENTS- PDS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | CTOS PDS | **Project Code** | PB4LSS0583 |
| **Virtual Project Manager** | Jae Eising | **Clinical Program Manager** | Nathan Kelly |
| **Compliance** | ---------- | **Editor** | Heather Tomlinson |

**Launch Date/Internal Launch Date:**

**10 December 2014**

**Project Type**

Webcast

Downloadable Slides

CD/DVD

Podcast

Other:

**Email Blast Included?**

Yes

No

Subject Line: New Downloadable Slides: Adding Precision and Power to Progress in Ovarian Cancer Management

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities: promote with GYN congress registration or save the date

**Target Audience**

US  
EX-US

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):   
Content Available by:

**CME?**

Yes

No

**CME Posttest Link:**

**Webcast/PDS URL:**

[www.prIMEoncology.org/pdsovarian\_melbourne](http://www.prIMEoncology.org/pdsovarian_melbourne)

**Additional Components**

Cases with Voting

Polls

Video Segmentation NA only slides

Table of Contents

Other:

**Mobile App Title: IGCS Ovarian Cancer PDS**

Global (Both EX-US & US)

Other or Special:

Additional Emails (Supporters?): see below

**Ilian.Tchakov@astrazeneca.com**

**Manoj.Prahladan@astrazeneca.com**

**LIVE MEETING-ASSOCIATED VIRTUAL ACTIVITIES**

1. **[Meeting-Associated Downloadable Slides]---VERIFY with Clinical after the meeting to see what presentation are to be included**

**Adding Precision and Power to Progress in Ovarian Cancer Management**

**ACTIVITY FEATURES**

[Icon] Downloadable Slides

[Insert screen shot]

**ACTIVITY OVERVIEW**

prIME Oncology invites you to view downloadable slides from *Adding Precision and Power to Progress in Ovarian Cancer Management*, a symposium held at IGCS 2014 in Melbourne, Australia.

~~\*\*\*May add a “in conjunction with \_\_\_\_\_\_\_” phrase if this is from a symposium at a congress.~~

**PROVIDER**

This activity is provided by prIME Oncology.

**TARGET AUDIENCE**

This activity is intended for medical oncologists, gynecologic oncologists, and other healthcare professionals involved in the treatment of patients with advanced ovarian cancer.

**LEARNING OBJECTIVES**

After successful completion of this educational activity, participants should be able to:

* Review the current recommendations for genetic testing for patients diagnosed with ovarian cancer
* Evaluate prognosis of patients with *BRCA1* and *BRCA2* mutations and identify the role of PARP inhibition as a potential emerging targeted therapy
* Examine recent data and ongoing trials of maintenance therapy in ovarian cancer, including patient selection for targeted therapy based on available biomarkers
* Describe  current and promising treatment options for relapsed platinum-sensitive ovarian cancer

**SUPPORTER**

This educational activity is supported by AstraZeneca.

**ACTIVITY DATE**

RELEASE DATE

10 December 2014

EXPIRATION DATE

10 December 2015

**[Tab—Ovarian Cancer]**

Discussant: **Clare Scott, MBBS, PhD,** The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

Topic: Know your enemy: The impact of *BRCA* status on management of ovarian cancer

Learning Objectives: Review the current recommendations for genetic testing for patients diagnosed with ovarian cancer

Evaluate prognosis of patients with *BRCA1* and *BRCA2* mutations and identify the role of PARP inhibition as a potential emerging targeted therapy

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Jonathan Ledermann, MD, FRCP,** UCL Cancer Institute, University College London, London, United Kingdom

Topic: Keeping the lid on ovarian cancer: Targeted therapeutic approaches

Learning Objective: Examine recent data and ongoing trials of maintenance therapy in ovarian cancer, including patient selection for targeted therapy based on available biomarkers

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Amit Oza, MD, FRCP, MBBS,** Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada

Topic: Platinum-sensitive relapsed ovarian cancer: New options on the horizon

Learning Objective: Describe current and promising treatment options for relapsed platinum-sensitive ovarian cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. **Web Activity Page Titles**

Landing Page Title:   
*Adding Precision and Power to Progress in Ovarian Cancer Management*

Activity Pages Titles:

1. **Meta Description  
   (One description for each page (including landing pages and all activity pages.** This should be roughly 150 characters in length. This is the short description that will appear beneath the activity title in search results, so it should be a compelling, keyword-rich description that will encourage the user to click)

Downloadable slides from the prIME Oncology satellite symposium, *Adding Precision and Power to Progress in Ovarian Cancer Management*, IGCS 2014, Melbourne, Australia.

1. **Key Words and Key Phrases  
   (Please included as many key words or phrases as are associated with the activity. 15 or more is ideal. These are words or phrases that a viewer might use in a web search. Please add one key word/phrase per line) Example:***ovarian cancer*

*Parp*

*Parp inhibitor*

*Maintenance*

*Platinum sensitive*